Tech Center 1700 • Art Units: 1656 1693 1754
This examiner grants 46% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17846696 | COMPOSITIONS COMPRISING ENZYMES | Final Rejection | The Procter & Gamble Company |
| 19264681 | PURIFIED PROTEIN COMPOSITIONS AND METHODS OF PRODUCTION | Final Rejection | Clara Foods Co. |
| 18452884 | CYCLIC LIPOPEPTIDE-PRODUCING MICROBIAL STRAIN AND METHOD FOR PRODUCING CYCLIC LIPOPEPTIDE | Non-Final OA | KANEKA CORPORATION |
| 17416814 | URINE STABILIZATION | Final Rejection | QIAGEN GmbH |
| 18036695 | MICROBIAL PRODUCTION OF TITIN FIBERS WITH EXCEPTIONAL MECHANICAL PERFORMANCE | Non-Final OA | Washington University |
| 18247616 | A DNA Assembly Mix And Method Of Uses Thereof | Non-Final OA | National University of Singapore |
| 17436338 | NON-VIRAL MODIFICATION OF MESENCHYMAL STEM CELLS | Non-Final OA | NATIONAL UNIVERSITY OF SINGAPORE |
| 18007274 | MUTANT INSECT OLFACTORY RECEPTOR PROTEIN | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 17908427 | PROTEINS WITH PREDICTABLE LIQUID-LIQUID PHASE SEPARATION | Non-Final OA | Duke University |
| 18707400 | 3D-PRINTING ENGINEERED LIVING MATERIALS | Non-Final OA | The Trustees of Princeton University |
| 18756409 | A PROCESS FOR MANUFACTURING A POTENTIATING PROTEIN COMPOSITION WITH INCREASED EFFICIENCY AND LONGEVITY AND USES THEREOF | Non-Final OA | 14787285 Canada Inc. dba Nuria Scientific |
| 18255869 | METHODS AND COMPOSITIONS FOR INHIBITING EXCESS NUCLEIC ACID PRECIPITATION | Non-Final OA | PFIZER INC. |
| 18020843 | REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 17995624 | GENE EXPRESSION SYSTEM FOR RAPID CONSTRUCTION OF MULTIPLE-GENE PATHWAY IN OLEAGINOUS YEASTS | Non-Final OA | WASHINGTON STATE UNIVERSITY |
| 17924204 | THERAPEUTIC OR PREVENTIVE AGENT FOR INFECTIOUS DISEASE | Final Rejection | NIPPON MEDICAL SCHOOL FOUNDATION |
| 17908761 | MODIFIED TRANSGLUTAMINASE | Final Rejection | Amano Enzyme Inc. |
| 18031301 | PROTEIN HAVING FERMENTED MILK VISCOSITY IMPROVING EFFECT, FERMENTED MILK USING THE SAME AND METHOD FOR PRODUCING THE SAME | Non-Final OA | MEIJI CO., LTD. |
| 18176546 | Compositions and Methods for Modulating Factor IX Function | Final Rejection | The Children's Hospital of Philadelphia |
| 18275255 | CELL CULTURE METHODS | Non-Final OA | DR. REDDY’S LABORATORIES LIMITED |
| 18280403 | GENE FOR EFFICIENTLY EXPRESSING HYALURONIC ACID HYDROLASE AND EXPRESSION METHOD THEREOF | Non-Final OA | BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED |
| 18016648 | METHODS AND SYSTEMS FOR PRODUCING POLYPEPTIDES | Non-Final OA | Seagen Inc. |
| 18253651 | LOW-DOSE HEPATOCYTE GROWTH FACTOR GENE THERAPY FOR DIABETES | Non-Final OA | KAGOSHIMA UNIVERSITY |
| 16627227 | AAV VECTOR COLUMN PURIFICATION METHODS | Non-Final OA | Spark Therapeutics, Inc. |
| 18254859 | RECOMBINANT MICROORGANISM HAVING IMPROVED ABILITY TO PRODUCE RECOMBINANT SILK PROTEIN AND METHOD FOR PRODUCING HIGH-MOLECULAR-WEIGHT RECOMBINANT SILK PROTEIN BY USING SAME | Non-Final OA | MEDICOSBIOTECH, INC |
| 17188173 | METHOD OF PURIFYING THERAPEUTIC PROTEINS | Final Rejection | CSL Behring GmbH |
| 18131968 | BIOSENSING ELEMENT BASED ON SPECIFIC BINDING OF CBM AND CELLULOSE | Non-Final OA | BIOLOGY INSTITUTE OF SHANDONG ACADEMY OF SCIENCES |
| 18296454 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | Final Rejection | SHANGHAI HEP PHARMACEUTICAL CO., LTD. |
| 18174319 | Preparation Method And Usage Method For Cartilage Tissue Recovery Collagen | Non-Final OA | Cellontech Co., Ltd. |
| 18020429 | METHOD FOR THE EFFICIENT EXPRESSION AND PURIFICATION AND APPLICATION OF A RECOMBINANT FUSION PROTEIN OF MANNASE AND HOMOLOGUES THEREOF AND GLP-1 | Non-Final OA | ANHUI NEW SIMON BIOTECH CO., LTD. |
| 18002806 | Compositions and Methods for Treating Hemorrhagic Shock | Non-Final OA | VirTech Bio, Inc |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy